InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,634.58
(
0.03%
)
US TECH 100
18,970.00
(
0.16%
)
Dow Jones
41,606.18
(
-0.04%
)
Brent Oil
72.29
(
-1.41%
)
Bitcoin
59,861.66
(
-0.73%
)
Post# of 253144
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120456
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Biowatch post# 31828

Tuesday, 07/25/2006 5:13:20 PM

Tuesday, July 25, 2006 5:13:20 PM

Post# of 253144
>It demonstrates that MNTA can sell its approach to big pharma.<

Two points:

1. The deal does not have an up-front signing fee per se—the initial $75M is all in the form of an equity sale.

2. MNTA now has essentially all of its future tied up with a single company (NVS). I think it would have been more bullish if MNTA had inked a major deal with a different partner.

--
MNTA’s valuation is not that cheap. Those who got out near today’s high (20.98) probably made a wise move, IMHO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up